Substance dependence

Addiction Policy Forum Launches New Chapter, Statewide Resource to Address Opioid Crisis in Kentucky

Retrieved on: 
Tuesday, June 19, 2018
Substance dependence, Psychiatry, Health, Psychiatric diagnosis, Addiction, Abnormal psychology, Opioid epidemic, Substance use disorder, Substance abuse

LOUISVILLE, Ky., June 19, 2018 /PRNewswire/ -- The Addiction Policy Forum (APF), a leading nonprofit tackling the opioid crisis, today announcedthe launch of its Kentucky chapter, led by state chair Jennifer Stepp.

Key Points: 
  • LOUISVILLE, Ky., June 19, 2018 /PRNewswire/ -- The Addiction Policy Forum (APF), a leading nonprofit tackling the opioid crisis, today announcedthe launch of its Kentucky chapter, led by state chair Jennifer Stepp.
  • To help people across the state who are struggling with substance use disorders, and to support their loved ones, APF also launched its Addiction Resource Center (ARC) in Kentucky.
  • The Addiction Resource Center website is a comprehensive, interactive portal that helps individuals and families struggling with addiction learn about substance use disorders and access help.
  • APF's eight strategic priorities include:
    Help Families in Crisis: Provide new, effective resources and support for patients and families in crisis.

Emergency Departments Help Close Gaps in Opioid Abuse and Addiction Treatment

Retrieved on: 
Thursday, June 14, 2018
Chemistry, RTT, Cell signaling, Morphinans, Neurochemistry, Substance dependence, Drug rehabilitation, Ethers, Buprenorphine, Opioid use disorder, Opioid, Addiction

MAT refers to addiction treatment with medications, most commonly buprenorphine, although it is most effective when combined with behavioral therapy and counseling.

Key Points: 
  • MAT refers to addiction treatment with medications, most commonly buprenorphine, although it is most effective when combined with behavioral therapy and counseling.
  • Coordinated care for complex chronic conditions is proven to be effective; treating opioid use disorder should be no different."
  • The authors make recommendations for opioid abuse screening, treatment and referrals in the emergency department.
  • Annals of Emergency Medicineis the peer-reviewed scientific journal for the American College of Emergency Physicians, the national medical society representing emergency medicine.

Geneva Company Announces U.S. Food and Drug Administration Clearance for Wearable Medical Device to Treat Drug Addiction

Retrieved on: 
Thursday, June 14, 2018
Substance dependence, Psychiatry, Euphoriants, Neuroscience, Morphine, Morphinans, Psychiatric diagnosis, Opioid use disorder, Addiction, Opioid, Substance use disorder, Psychology

GENEVA, June 14, 2018 /PRNewswire/ --DyAnsys Europe SARL has announced that its parent company, DyAnsys Inc., has U.S. Food and Drug Administration clearance for an auricular neurostimulation device to treat the symptoms of opioid withdrawal without narcotics.

Key Points: 
  • GENEVA, June 14, 2018 /PRNewswire/ --DyAnsys Europe SARL has announced that its parent company, DyAnsys Inc., has U.S. Food and Drug Administration clearance for an auricular neurostimulation device to treat the symptoms of opioid withdrawal without narcotics.
  • This wearable device sends electrical pulses through tiny needles inserted in the ear to alleviate symptoms such as anxiety, agitation, depression, nausea, opiate cravings and more.
  • "This device offers hope to those who are suffering from opioid addiction," said DyAnsys Chief Executive Officer Srini Nageshwar.
  • Opioids accounted for 70 percent of the negative health impact associated with drug use disorders UNDOC reported in last year's World Drug Report.

U.S. Food and Drug Administration Clears Wearable Device to Treat Opioid Addiction

Retrieved on: 
Tuesday, June 12, 2018
Chemistry, RTT, Substance dependence, Euphoriants, Morphinans, Morphine, Organic chemistry, Opioid use disorder, Neuroscience, Addiction, Opioid, Substance abuse

Drug Relief is available now for providers to prescribe for use during opioid detoxification.

Key Points: 
  • Drug Relief is available now for providers to prescribe for use during opioid detoxification.
  • This wearable device sends electrical pulses through tiny needles inserted in the ear to alleviate symptoms such as anxiety, agitation, depression, nausea, opiate cravings and more.
  • "This device offers hope to those who are suffering from opioid addiction," said DyAnsys Chief Executive Officer Srini Nageshwar.
  • More than 2.5 million Americans suffer from opioid use disorder, according to the National Institutes on Drug Abuse.

Risky Drinking Can Put a Chill on Your Summer Fun

Retrieved on: 
Tuesday, June 12, 2018
Drinking culture, RTT, Alcohol abuse, Alcoholism, Psychiatric diagnosis, Substance dependence, Human behavior, Health

For many people, a day at the beach, on the boat, or at a backyard barbecue will include drinking alcoholic beverages.

Key Points: 
  • For many people, a day at the beach, on the boat, or at a backyard barbecue will include drinking alcoholic beverages.
  • But risky drinking and summer activities don't mix.
  • The summer holidays are some of the most dangerous times of the year to be on the road.
  • For more information on preventing problems with alcohol this summer, and tips on cutting back, visit: https://www.rethinkingdrinking.niaaa.nih.gov
    1 Driscoll, T.R.

The Partnership for a Drug-Free New Jersey Takes Best of Public Relations Trophy at 50th Annual NJ Ad Club Jersey Awards

Retrieved on: 
Monday, June 11, 2018
Health, Government, Psychiatry, Drugs in the United States, Opioid epidemic, Substance dependence, Prosecutor, Recovery approach, Pro bono, Opioid, Horizon

The town hall series also received first place in the Public Relations: Not for Profit/Pro Bono Work category, one of four first-place trophies PDFNJ won at the awards ceremony.

Key Points: 
  • The town hall series also received first place in the Public Relations: Not for Profit/Pro Bono Work category, one of four first-place trophies PDFNJ won at the awards ceremony.
  • The town hall series, supported by a grant from The Horizon Foundation for New Jersey, began in April 2017 and featured events for audiences from every county in the state.
  • The events included participation from county prosecutors, state legislators, doctors and professionals from the prevention, treatment and recovery fields.
  • We're very proud to be honored by the NJ Ad Club and we remain committed to addressing the opioid crisis in the Garden State."

Addiction Policy Forum Launches Statewide Resource to Address the Opioid Crisis in Oregon

Retrieved on: 
Monday, June 11, 2018
Substance dependence, Psychiatry, Health, Psychiatric diagnosis, Substance abuse, Addiction, Opioid epidemic, Substance use disorder

PORTLAND, Ore., June 11, 2018 /PRNewswire/ --The Addiction Policy Forum, a leading nonprofit tackling the opioid crisis, has launched its Addiction Resource Center (ARC) for people across Oregon who are struggling with substance use disorder, as well as their loved ones.

Key Points: 
  • PORTLAND, Ore., June 11, 2018 /PRNewswire/ --The Addiction Policy Forum, a leading nonprofit tackling the opioid crisis, has launched its Addiction Resource Center (ARC) for people across Oregon who are struggling with substance use disorder, as well as their loved ones.
  • "Hundreds of Oregon families have been affected by the opioid crisis.
  • The Addiction Resource Center is a comprehensive, interactive website to help individuals and families struggling with addiction learn about substance use disorders and access help.
  • "Having the ARC phone line and online portal available in Oregon is a critical addition to our state's response to addiction."

Pharmaleads Presents New Data Showing DENKIs, a New Class of Painkillers, to be Devoid of Abuse Potential and Opiate Side-Effects

Retrieved on: 
Monday, June 11, 2018
Pain, Perception, Acute pain, Nociception, Substance dependence, Opiates, Pain management, Palliative care, Opioid epidemic, Opioid, Addiction, Opioid rotation

"The data presented shows that PL265 and PL37 are devoid of any abuse potential even at high doses and after repeated administration while providing similar levels of pain relief to opiates, but without their side-effects," said Michel Wurm, VP Medical Affairs at Pharmaleads.

Key Points: 
  • "The data presented shows that PL265 and PL37 are devoid of any abuse potential even at high doses and after repeated administration while providing similar levels of pain relief to opiates, but without their side-effects," said Michel Wurm, VP Medical Affairs at Pharmaleads.
  • "Our DENKIs have the potential to offer a solution to the opioid crisis by providing safe and non-addictive relief to patients suffering from multiple types of severe pain."
  • Pharmaleads' drugs are based on its deep knowledge and understanding of enkephalins, a key element of the body's natural pain management system.
  • Pharmaleads has two compounds in clinical development which are targeting multi-billion markets:
    Pharmaleads is headquartered in Paris, France, and is funded by private investors.

Can Your DNA Predict Opioid Addiction? New Research Partnership Between Bentley University and Gravity Diagnostics Will Explore the Genetic Link to Opioid Abuse

Retrieved on: 
Monday, June 11, 2018
Abnormal psychology, Addiction, Opioid, RTT, Substance dependence, Neuroscience, Psychiatry, Brain

The research tackles a critical issue in the United States today -- the slide from prescription opioid use into addiction.

Key Points: 
  • The research tackles a critical issue in the United States today -- the slide from prescription opioid use into addiction.
  • The project will provide hands-on learning opportunities for Bentley students, who will help process and enter the data and write computer scripts.
  • It is funded by a $360,000 grant from Gravity Diagnostics , a laboratory based in Northern Kentucky.
  • Once identified, the genetic features and predictions will be tested by comparing them to the DNA of current opioid addicts and those in recovery.

ONDCP, Truth Initiative and the Ad Council Join Forces on National Effort to Fight Opioid Misuse Among America's Youth and Young Adults

Retrieved on: 
Thursday, June 7, 2018
Metaphysics, Smoking in the United States, Tobacco control, Substance dependence, Truth Initiative, Truth, Opioid

Our partnership with the Ad Council and Truth Initiative is designed to reduce stigma, increase awareness and inspire action, and save lives.

Key Points: 
  • Our partnership with the Ad Council and Truth Initiative is designed to reduce stigma, increase awareness and inspire action, and save lives.
  • The Office of National Drug Control Policy is pleased to unveil The Truth About Opioids Campaign with our partners at the Truth Initiative and the Ad Council.
  • Created by Truth Initiative, the national public health organization behind the truth campaign, the first installment of The Truth About Opioid's multi-phased effort, featuresfirst-person, true stories of young Americans with opioid use disorder.
  • Truth Initiative, through its truth campaign, offers an unmatched expertise and record of success in public education programs targeted to youth and young adults.